Abstract:Abstract Background Crossover designs are commonly utilised in randomised controlled trials investigating treatments for long-term chronic illnesses. One problem with this design is its inherent repeated measures necessitate the availability of an estimate of the within-person standard deviation (SD) to perform a sample size calculation, which may be rarely available at the design stage of a trial. Interim sample size re-estimation designs can be used to help alleviate this issue by adapting the sample size mid-way through the trial, using accrued information in a statistically robust way. Methods The AIM HY-INFORM study is part of the Informative Markers in Hypertension (AIM HY) Programme and comprises two crossover trials, each with a planned recruitment of 600 participants. The objective of the study is to test whether blood pressure response to first line antihypertensive treatment depends on ethnicity. An interim analysis is planned to reassess the assumptions of the planned sample size for the study. The aims of this paper are: (1) to provide a formula for sample size re-estimation in both crossover trials; and (2) to present a simulation study of the planned interim analysis to investigate alternative within-person SDs to that assumed. Results The AIM HY-INFORM protocol sample size calculation fixes the within-person SD to be 8 mmHg, giving > 90% power for a primary treatment effect of 4 mmHg. Using the method developed here and simulating the interim sample size reassessment, if we were to see a larger within-person SD of 9 mmHg at interim, 640 participants for 90% power 90% of the time in the three-period three-treatment design would be required. Similarly, in the four-period four-treatment crossover design, 602 participants would be required. Conclusions The formulas presented here provide a method for re-estimating the sample size in crossover trials. In the context of the AIM HY-INFORM study, simulating the interim analysis allows us to explore the results of a possible increase in the within-person SD from that assumed. Simulations show that without increasing the planned sample size of 600 participants, we can reasonably still expect to achieve 80% power with a small increase in the within-person SD from that assumed. Trial registration ClinicalTrials.gov, NCT02847338 . Registered on 28 July 2016.

Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation.

Sample size re-estimation in a superiority clinical trial using a hybrid classical and Bayesian procedure

Adaptive two-stage seamless sequential design for clinical trials

Sample Size Reestimation in Stochastic Curtailment Tests With Time‐to‐Events Outcome in the Case of Nonproportional Hazards Utilizing Two Weibull Distributions With Unknown Shape Parameters

A Practical Simulation Method to Calculate Sample Size of Group Sequential Trials for Time-to-Event Data under Exponential and Weibull Distribution

Familywise error for multiple time‐to‐event endpoints in a group sequential design

First person: a mental health mission to post-earthquake El Salvador.

The Conditional Power of Interim Analysis and Sample Size Re-estimation

BOP2: Bayesian Optimal Design for Phase II Clinical Trials with Simple and Complex Endpoints.

Sequential Continual Reassessment Method for Two-Dimensional Dose Finding.

Analysis of innovative two-stage seamless adaptive design with different endpoints and population shift

Estimation of treatment effects following a sequential trial of multiple treatments

A two‐stage group‐sequential design for delayed treatment responses with the possibility of trial restart

A Nonparametric Global Win Probability Approach to the Analysis and Sizing of Randomized Controlled Trials With Multiple Endpoints of Different Scales and Missing Data: Beyond O'Brien–Wei–Lachin

Sample size re-estimation in crossover trials: application to the AIM HY-INFORM study

Optimization the Design of Fixed and Group Sequential Three-Arm Non-Inferiority Trials with Dichotomous Endpoints of Risk Difference and Odds Ratio

Group sequential designs for clinical trials when the maximum sample size is uncertain

Stochastic curtailment tests for phase II trial with time-to-event outcome using the concept of relative time in the case of non-proportional hazards

Two‐stage randomized clinical trials with a right‐censored endpoint: Comparison of frequentist and Bayesian adaptive designs

New strategies for confirmatory testing of secondary hypotheses on combined data from multiple trials

Design optimisation and post-trial analysis in group sequential stepped-wedge cluster randomised trials